首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

2131472

全球疫苗佐劑市場

Global Vaccine Adjuvants Market

出版日期: 2026年09月01日 | 出版商:

BCC Research | 英文 124 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

本報告對全球疫苗佐劑市場進行了分析。

本報告重點關注關鍵成長要素和挑戰。該研究評估了競爭格局，檢驗了主要技術發展趨勢，並提供了直至2031年的市場估算和預測。

調查範圍

本報告概述了全球疫苗佐劑市場。報告包含以2025年為基準年的全球銷售額數據（單位：百萬美元），並對2026年估計值，同時預測至2031年。市場按產品類型、疾病類型、疫苗類型、給藥途徑、應用領域和地區進行細分。依產品類型分類，疫苗佐劑可分為顆粒佐劑、乳化佐劑、皂素佐劑、Toll樣受體（TLR）促效劑及其他佐劑。依疾病類型分類，市場可分為感染疾病、癌症和其他疾病。本研究涵蓋的地區包括北美、歐洲、亞太地區、南美以及中東和非洲，並聚焦於各地區的主要國家。

本報告重點介紹了影響市場的關鍵趨勢和挑戰，並包括對專利、臨床試驗和新興技術的分析和見解。

本報告最後分析了競爭格局，顯示了全球疫苗佐劑市場主要參與者的排名和市場佔有率。專門的公司簡介部分提供了有關主要參與者的信息，例如葛蘭素史克公司 (GSK Plc.)、CSL、諾瓦瓦克斯公司 (Novavax)、科萊恩國際公司 (Croda International Plc.)、戴納瓦克斯科技公司 (Dynavax Technologies Corp.)、Avanti Research、Desert King、戴納瓦克斯科技公司 (Dynavax Technologies Corp.)、Avanti Research、Desert King、Invial、SpEP、PIC 和 PharmaEP。

報告內容

對全球用於人類和動物疫苗生產的疫苗佐劑化合物和系統市場進行分析。
全球趨勢分析，包括 2023 年至 2025 年的歷史數據、2026 年的估計值以及到 2031 年的複合年成長率預測。
全球市場規模、估算和收入預測，以及按產品類型、疾病類型、疫苗類型、給藥途徑、應用和地區分類的市場佔有率分析。
有關市場動態的影響、糖尿病管理領域的最新技術進步、法規、前景和宏觀經濟變數的事實和數據。
基於波特五力模型和全球供應鏈分析的見解。
對臨床定序。
專利綜述，重點介紹已註冊和已公佈的主要專利
產業結構分析，包括公司市場佔有率和排名、產品佈局、策略舉措、併購活動和創業融資前景。
概述永續發展趨勢和ESG進展。重點關注消費者意識以及大型企業對ESG風險的評估和實施。
主要全球公司簡介

市場定義
各種類型的疫苗佐劑
佐劑在各種疫苗中的作用
疫苗佐劑的未來
波特五力分析
新進入者的威脅（低）
競爭強度
宏觀經濟因素分析
經濟成長和醫療保健支出
感染疾病和慢性病盛行率增加
監管因素
技術進步
美國關稅法對疫苗佐劑市場的影響

第3章市場動態

市場動態
市場促進因素
佐劑在現代疫苗平台中的關鍵作用
擴大全球免疫規劃並提高疫苗接種率
對獸醫疫苗接種和牲畜疾病管制的需求日益成長。
下一代佐劑的技術進步
市場限制因素
嚴格的監管要求和臨床有效性要求
輔助治療的副作用和毒性
特殊佐劑成分的供應鏈限制
市場機遇
開發先進的聯合治療精準輔助治療系統
擴大治療藥物和癌症疫苗的研發
伴侶動物市場的成長

第4章監管情勢

概述
國家/地區特定法規和標準

第5章：新興技術與專利分析

概述
新興技術
精密複合佐劑系統的開發
先進佐劑可擴展合成製造
奈米結構和脂質遞送平台整合了免疫刺激功能
臨床試驗分析
依研究類型進行臨床試驗分析
臨床試驗進展分析
分階段臨床試驗分析
專利分析
按年份統計的專利數量
由頂尖申請者
由頂級所有者撰寫
按管轄權

第6章市場區隔分析

細分市場
疫苗佐劑市場：依產品類型分類
顆粒佐劑
乳劑輔料
皂素類佐劑
TLR促效劑
其他佐劑
疾病特異性疫苗佐劑市場
感染疾病
癌症
其他疾病
疫苗佐劑市場：依疫苗類型分類
人用疫苗
動物疫苗
疫苗佐劑市場：依應用領域分類
商業用途
研究應用
疫苗佐劑市場：依給藥途徑分類
肌肉內部
皮下
皮內注射
其他給藥途徑
按地區分類
疫苗佐劑市場（按地區分類）
北美洲
歐洲
亞太地區
南美洲
中東和非洲

第7章競爭情勢

競爭格局
主要公司的全球市場佔有率
戰略分析

第8章附錄

調查方法
參考
簡稱
公司簡介
AVANTI RESEARCH
CRODA INTERNATIONAL PLC
CSL
DESERT KING
DYNAVAX TECHNOLOGIES CORP.
GSK PLC
INVIVOGEN
NOVAVAX
SEPPIC
SPI PHARMA
新興創業公司/市場顛覆者

簡介目錄圖表

Product Code: PHM293A

This report provides an analysis of the global market for vaccine adjuvants. It focuses on the key driving trends and challenges. The study evaluates the competitive landscape, reviews key technological developments, and provides market estimates and forecasts through 2031.

Report Scope

This report provides an overview of the global vaccine adjuvants market. It includes global revenue ($ millions), with 2025 as the base year, estimates for 2026, and forecasts through 2031. The market is segmented by product type, disease type, vaccine type, route of administration, application, and region. Based on product type, vaccine adjuvants are categorized into particulate-based adjuvants, emulsion adjuvants, saponin-based adjuvants, Toll-like receptor (TLR) agonists, and other adjuvants. Based on disease type, the market is categorized into infectious diseases, cancer, and other diseases. The regions covered in this study include North America, Europe, Asia-Pacific, South America, and the Middle East and Africa, with a focus on major countries in each region.

The report highlights the key trends and challenges affecting the market, along with analysis and discussions regarding patents, clinical trials, and emerging technologies.

The report concludes with an analysis of the competitive landscape, which provides rankings and market shares for key companies in the global vaccine adjuvants market. A dedicated company profile section provides information on leading companies, including GSK Plc., CSL, Novavax, Croda International Plc., Dynavax Technologies Corp., Avanti Research, Desert King, InvivoGen, SEPPIC, and SPI Pharma.

Report Includes

An analysis of the global markets for vaccine adjuvant compounds and systems used in human and veterinary vaccines production
Analyses of the global market trends, with historic data from 2023 to 2025, estimates for 2026 and projections of CAGRs through 2031
Estimates of the market size and revenue prospects for global market, accompanied by a market share analysis by product type, disease type, vaccine type, route of administration, application, and region
Facts and figures pertaining to the market dynamics, recent technological advancements in diabetes management, regulations, prospects and the impact of macroeconomic variables
Insights derived from Porter's Five Forces model, as well as global supply chain analyses
Review of emerging technologies, market applications, industry structure, and key initiatives in clinical sequencing
Patent review, featuring key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
Profiles of the leading global companies

Chapter 1 Executive Summary

Market Outlook
Scope of the Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Market Definition
Different Categories of Vaccine Adjuvants
Role of Adjuvants in Different Vaccine Types
Future of Vaccine Adjuvants
Porter's Five Forces Analysis
Threat of New Entrants (Low)
Bargaining Power of Buyers (High)
Bargaining Power of Suppliers (Moderate)
Threat of Substitutes (Low)
Level of Competitiveness (Moderate)
Macroeconomic Factors Analysis
Economic Growth and Healthcare Spending
Rising Prevalence of Infectious and Chronic Diseases
Regulatory Factors
Technological Developments
Impact of U.S. Tariff Laws on the Vaccine Adjuvants Market

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Essential Role of Adjuvants in Modern Vaccine Platforms
Expansion of Global Immunization Programs and Vaccine Coverage
Rising Veterinary Vaccination and Livestock Disease-Control Needs
Technological Developments in Next-Generation Adjuvants
Market Restraints
High Regulatory and Clinical Validation Requirements
Side Effects and Toxicity of Adjuvants
Supply Chain Constraints for Specialized Adjuvant Components
Market Opportunities
Development of Advanced Combination and Precision Adjuvant Systems
Expansion of Therapeutic and Cancer Vaccine Development
Growth in the Companion Animal Market

Chapter 4 Regulatory Landscape

Overview
Regulations and Standards by Select Country or Region

Chapter 5 Emerging Technologies and Patent Analysis

Overview
Emerging Technologies
Development of Precision Combination Adjuvant Systems
Scalable and Synthetic Production of Advanced Adjuvants
Nanostructured and Lipid-Based Delivery Platforms with Integrated Immunostimulation
Clinical Trial Analysis
Key Takeaways
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Patent Analysis
Key Takeaways
Patents, by Year
By Top Applicant
By Top Owner
By Jurisdiction

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Vaccine Adjuvants Market, by Product Type
Key Takeaways
Particulate-Based Adjuvants
Emulsion Adjuvants
Saponin-Based Adjuvants
TLR Agonists
Other Adjuvants
Vaccine Adjuvants Market, by Disease Type
Key Takeaways
Infectious Diseases
Cancer
Other Diseases
Vaccine Adjuvants Market, by Vaccine Type
Key Takeaways
Human Vaccines
Veterinary Vaccines
Vaccine Adjuvants Market, by Application
Key Takeaways
Commercial Applications
Research Applications
Vaccine Adjuvants Market, by Route of Administration
Key Takeaways
Intramuscular
Subcutaneous
Intradermal
Other Routes of Administration
Geographic Breakdown
Vaccine Adjuvants Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa

Chapter 7 Competitive Intelligence

Key Takeaways
Competitive Landscape
Global Market Shares of Leading Companies
Strategic Analysis

Chapter 8 Appendix

Research Methodology
References
Abbreviations
Company Profiles
AVANTI RESEARCH
CRODA INTERNATIONAL PLC
CSL
DESERT KING
DYNAVAX TECHNOLOGIES CORP.
GSK PLC
INVIVOGEN
NOVAVAX
SEPPIC
SPI PHARMA
A Few Emerging Start-ups/Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for Vaccine Adjuvants, by Region, Through 2031
Table 1 : Key Limitations of Traditional Vaccine Adjuvants
Table 2 : Advantages of Next-Generation Vaccine Adjuvants
Table 3 : Categories of Vaccine Adjuvants and Their Mechanisms
Table 4 : Role of Adjuvants in Different Vaccine Types
Table 5 : Porter's Five Forces: Rating Scale
Table 6 : U.S. Pet Ownership Statistics, Dogs and Cats, 2025
Table 7 : Regulatory Landscape Governing Vaccine Adjuvants, by Country/Region
Table 8 : Clinical Trials for Vaccine Adjuvants, by Type of Study, as of March 2026
Table 9 : Clinical Trials for Vaccine Adjuvants, by Status, as of March 2026
Table 10 : Clinical Trials for Vaccine Adjuvants, by Phase, as of March 2026
Table 11 : Notable Patents, by Top Applicants, 2024-2025
Table 12 : Patents, by Top Owner, 2024-2025
Table 13 : Patents, by Jurisdiction, 2024-2025
Table 14 : Global Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 15 : Global Vaccine Adjuvants Market for Particulate-Based Adjuvants, by Region, Through 2031
Table 16 : Global Vaccine Adjuvants Market for Emulsion Adjuvants, by Region, Through 2031
Table 17 : Global Vaccine Adjuvants Market for Saponin-Based Adjuvants, by Region, Through 2031
Table 18 : Global Vaccine Adjuvants Market for TLR Agonists, by Region, Through 2031
Table 19 : Global Vaccine Adjuvants Market for Other Adjuvants, by Region, Through 2031
Table 20 : Global Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 21 : Global Vaccine Adjuvants Market for Infectious Diseases, by Region, Through 2031
Table 22 : Global Vaccine Adjuvants Market for Cancer, by Region, Through 2031
Table 23 : Global Vaccine Adjuvants Market for Other Diseases, by Region, Through 2031
Table 24 : Global Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 25 : Global Vaccine Adjuvants Market for Human Vaccines, by Region, Through 2031
Table 26 : Global Vaccine Adjuvants Market for Veterinary Vaccines, by Region, Through 2031
Table 27 : Global Market for Vaccine Adjuvants, by Application, Through 2031
Table 28 : Global Vaccine Adjuvants Market for Commercial Applications, by Region, Through 2031
Table 29 : Global Vaccine Adjuvants Market for Research Applications, by Region, Through 2031
Table 30 : Global Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 31 : Global Vaccine Adjuvants Market for Intramuscular Route of Administration, by Region, Through 2031
Table 32 : Global Vaccine Adjuvants Market for Subcutaneous Route of Administration, by Region, Through 2031
Table 33 : Global Vaccine Adjuvants Market for Intradermal Route of Administration, by Region, Through 2031
Table 34 : Global Vaccine Adjuvants Market for Other Routes of Administration, by Region, Through 2031
Table 35 : Global Market for Vaccine Adjuvants, by Region, Through 2031
Table 36 : North American Market for Vaccine Adjuvants, by Country, Through 2031
Table 37 : North American Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 38 : North American Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 39 : North American Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 40 : North American Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 41 : North American Market for Vaccine Adjuvants, by Application, Through 2031
Table 42 : European Market for Vaccine Adjuvants, by Country, Through 2031
Table 43 : European Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 44 : European Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 45 : European Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 46 : European Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 47 : European Market for Vaccine Adjuvants, by Application, Through 2031
Table 48 : Asia-Pacific Market for Vaccine Adjuvants, by Country, Through 2031
Table 49 : Asia-Pacific Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 50 : Asia-Pacific Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 51 : Asia-Pacific Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 52 : Asia-Pacific Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 53 : Asia-Pacific Market for Vaccine Adjuvants, by Application, Through 2031
Table 54 : South American Market for Vaccine Adjuvants, by Country, Through 2031
Table 55 : South American Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 56 : South American Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 57 : South American Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 58 : South American Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 59 : South American Market for Vaccine Adjuvants, by Application, Through 2031
Table 60 : MEA Market for Vaccine Adjuvants, by Sub-region, Through 2031
Table 61 : MEA Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 62 : MEA Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 63 : MEA Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 64 : MEA Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 65 : MEA Market for Vaccine Adjuvants, by Application, Through 2031
Table 66 : Leading Providers of Vaccine Adjuvants, 2025
Table 67 : Recent Developments in the Vaccine Adjuvants Market, January 2023-March 2026
Table 68 : Abbreviations Used in the Report
Table 69 : Avanti Research: Company Snapshot
Table 70 : Avanti Research: Product Portfolio
Table 71 : Avanti Research: News/Key Developments, 2025
Table 72 : Croda International Plc: Company Snapshot
Table 73 : Croda International Plc: Financial Performance, FY 2024 and 2025
Table 74 : Croda International Plc: Product Portfolio
Table 75 : Croda International Plc: News/Key Developments, 2023-2024
Table 76 : CSL.: Company Snapshot
Table 77 : CSL: Financial Performance, FY 2023 and 2024
Table 78 : CSL: Product Portfolio
Table 79 : CSL: News/Key Developments, 2024
Table 80 : Desert King: Company Snapshot
Table 81 : Desert King: Product Portfolio
Table 82 : Desert King: News/Key Developments, 2025
Table 83 : Dynavax Technologies Corp.: Company Snapshot
Table 84 : Dynavax Technologies Corp.: Product Portfolio
Table 85 : Dynavax Technologies Corp.: News/Key Developments, 2023-2026
Table 86 : GSK plc: Company Snapshot
Table 87 : GSK plc: Financial Performance, FY 2024 and 2025
Table 88 : GSK plc: Product Portfolio
Table 89 : GSK plc: News/Key Developments, 2023-2025
Table 90 : InvivoGen: Company Snapshot
Table 91 : InvivoGen: Product Portfolio
Table 92 : InvivoGen: News/Key Developments, 2024
Table 93 : Novavax: Company Snapshot
Table 94 : Novavax: Financial Performance, FY 2024 and 2025
Table 95 : Novavax: Product Portfolio
Table 96 : Novavax: News/Key Developments, 2024-2026
Table 97 : SEPPIC: Company Snapshot
Table 98 : SEPPIC: Product Portfolio
Table 99 : SEPPIC: News/Key Developments, 2025
Table 100 : SPI PHARMA: Company Snapshot
Table 101 : SPI PHARMA: Product Portfolio
Table 102 : SPI PHARMA: News/Key Developments, 2024
Table 103 : List of a Few Emerging Startups/Market Disruptors

List of Figures

Summary Figure : Summary Figure: Global Market Shares for Vaccine Adjuvants, by Region, 2025
Figure 1 : Porter's Five Forces Analysis: Vaccine Adjuvants Market
Figure 2 : Market Dynamics of Vaccine Adjuvants
Figure 3 : Emerging Technologies in the Vaccine Adjuvants Market
Figure 4 : Patents Granted, by Year, 2024-2025
Figure 5 : Global Market Shares for Vaccine Adjuvants, by Product Type, 2025
Figure 6 : Global Vaccine Adjuvants Market Shares for Particulate-Based Adjuvants, by Region, 2025
Figure 7 : Global Vaccine Adjuvants Market Shares for Emulsion Adjuvants, by Region, 2025
Figure 8 : Global Vaccine Adjuvants Market Shares for Saponin-Based Adjuvants, by Region, 2025
Figure 9 : Global Vaccine Adjuvants Market Shares for TLR Agonists, by Region, 2025
Figure 10 : Global Vaccine Adjuvants Market Shares for Other Adjuvants, by Region, 2025
Figure 11 : Global Market Shares for Vaccine Adjuvants, by Disease Type, 2025
Figure 12 : Global Vaccine Adjuvants Market Shares for Infectious Diseases, by Region, 2025
Figure 13 : Global Vaccine Adjuvants Market Shares for Cancer, by Region, 2025
Figure 14 : Global Vaccine Adjuvants Market Shares for Other Diseases, by Region, 2025
Figure 15 : Global Market Shares for Vaccine Adjuvants, by Vaccine Type, 2025
Figure 16 : Global Vaccine Adjuvants Market Shares for Human Vaccines, by Region, 2025
Figure 17 : Global Vaccine Adjuvants Market Shares for Veterinary Vaccines, by Region, 2025
Figure 18 : Global Market Shares for Vaccine Adjuvants, by Application, 2025
Figure 19 : Global Vaccine Adjuvants Market Shares for Commercial Applications, by Region, 2025
Figure 20 : Global Vaccine Adjuvants Market Shares for Research Applications, by Region, 2025
Figure 21 : Global Market Shares for Vaccine Adjuvants, by Route of Administration, 2025
Figure 22 : Global Vaccine Adjuvants Market Shares for Intramuscular Route of Administration, by Region, 2025
Figure 23 : Global Vaccine Adjuvants Market Shares for Subcutaneous Route of Administration, by Region, 2025
Figure 24 : Global Vaccine Adjuvants Market Shares for Intradermal Route of Administration, by Region, 2025
Figure 25 : Global Vaccine Adjuvants Market Shares for Other Routes of Administration, by Region, 2025
Figure 26 : Global Market Shares for Vaccine Adjuvants, by Region, 2025
Figure 27 : North American Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 28 : European Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 29 : Asia-Pacific Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 30 : South American Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 31 : MEA Market Shares for Vaccine Adjuvants, by Sub-region, 2025
Figure 32 : Global Market Share Analysis for Vaccine Adjuvants, by Company, 2025
Figure 33 : Croda International Plc: Revenue Shares, by Business Unit, FY 2025
Figure 34 : Croda International Plc: Revenue Shares, by Region/Country, FY 2025
Figure 35 : CSL: Revenue Shares, by Business Unit, FY 2024
Figure 36 : CSL: Revenue Shares, by Region/Country, FY 2024
Figure 37 : GSK plc: Revenue Shares, by Business Unit, FY 2025
Figure 38 : GSK Plc: Revenue Shares, by Region/Country, FY 2025
Figure 39 : Novavax: Revenue Shares, by Business Unit, FY 2025
Figure 40 : Novavax: Revenue Shares, by Region/Country, FY 2025